Biotech Values

[apljack]

NEO Neogenomics is gapping up today on no news. The scuttlebutt on YMB is that the decision by CMS to increase pathology testing reimbursement by 8% may be the cause. The company reports on 7/23. I anticipate numbers that beat the street estimates, but this kind of move suggests that something else is also in the works.

Here's the PR about reimbursement:

http://www.medpagetoday.com/PracticeManagement/Reimbursement/52505

There is also some "pain" in the CMS proposal: gastroenterologists are getting cut 5% and radiation oncologists face a 3% pay cut. But pathologists are the big winners with an 8% raise.